The molecular mechanism of Vav 3 oncogene on upregulation of androgen receptor activity in prostate cancer cells

[1]  Zhongyun Dong,et al.  Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer , 2008, BMC Cancer.

[2]  K. Burnstein,et al.  Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. , 2008, Molecular endocrinology.

[3]  Jayoung Kim,et al.  Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes , 2007, Steroids.

[4]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[5]  M. Revelo,et al.  Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. , 2006, Molecular endocrinology.

[6]  Dana M. Brantley-Sieders,et al.  Essential Role of Vav Family Guanine Nucleotide Exchange Factors in EphA Receptor-Mediated Angiogenesis , 2006, Molecular and Cellular Biology.

[7]  K. Burnstein,et al.  Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. , 2006, Molecular endocrinology.

[8]  C. Haiman,et al.  Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Bilancio,et al.  Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. , 2005, Cancer research.

[10]  M. Hung,et al.  The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. , 2005, Endocrine-related cancer.

[11]  S. Hammes,et al.  The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. , 2005, Molecular endocrinology.

[12]  M. Freeman,et al.  Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer , 2005, Trends in Endocrinology & Metabolism.

[13]  K. Burnstein,et al.  Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy , 2005, Journal of cellular biochemistry.

[14]  G. Bartsch,et al.  Expression and function of androgen receptor coactivators in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[16]  Brian T. Chait,et al.  E Protein Silencing by the Leukemogenic AML1-ETO Fusion Protein , 2004, Science.

[17]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[18]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[19]  C. Rochette-Egly.  Nuclear receptors: integration of multiple signalling pathways through phosphorylation. , 2003, Cellular signalling.

[20]  J. Downward,et al.  Mechanism of Epidermal Growth Factor Regulation of Vav2, a Guanine Nucleotide Exchange Factor for Rac* , 2003, The Journal of Biological Chemistry.

[21]  X. Bustelo,et al.  Structural Determinants for the Biological Activity of Vav Proteins* , 2002, The Journal of Biological Chemistry.

[22]  L. Wang,et al.  Distinct Role of Phosphatidylinositol 3-Kinase and Rho Family GTPases in Vav3-induced Cell Transformation, Cell Motility, and Morphological Changes* , 2002, The Journal of Biological Chemistry.

[23]  N. Varin‐Blank,et al.  Vav1 Is a Component of Transcriptionally Active Complexes , 2002, The Journal of experimental medicine.

[24]  M. Freeman,et al.  Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. , 2002, Cancer research.

[25]  Brian T Chait,et al.  The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. , 2002, Molecular cell.

[26]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[27]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[28]  X. Bustelo.  Vav proteins, adaptors and cell signaling , 2001, Oncogene.

[29]  Tetsurou Matsumoto,et al.  Different expression of androgen receptor coactivators in human prostate. , 2001, Urology.

[30]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[31]  J. Richie,et al.  Caveolin-1 Interacts with Androgen Receptor , 2001, The Journal of Biological Chemistry.

[32]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[33]  John D. Welsh,et al.  Vav3 Mediates Receptor Protein Tyrosine Kinase Signaling, Regulates GTPase Activity, Modulates Cell Morphology, and Induces Cell Transformation , 2000, Molecular and Cellular Biology.

[34]  Xin-Yun Huang,et al.  Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation , 2000, Cell.

[35]  Frederick W. Alt,et al.  Vav Family Proteins Couple to Diverse Cell Surface Receptors , 2000, Molecular and Cellular Biology.

[36]  X. Bustelo,et al.  Tyrosine Phosphorylation Mediates Both Activation and Downmodulation of the Biological Activity of Vav , 2000, Molecular and Cellular Biology.

[37]  X. Bustelo.  Regulatory and Signaling Properties of the Vav Family , 2000, Molecular and Cellular Biology.

[38]  X. Bustelo,et al.  Biological and Regulatory Properties of Vav-3, a New Member of the Vav Family of Oncoproteins , 1999, Molecular and Cellular Biology.

[39]  M. Tsai,et al.  Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells1. , 1999, Endocrinology.

[40]  G. Cardi,et al.  Chemotherapy in advanced prostate cancer. , 1999, Seminars in oncology.

[41]  V. Giguère,et al.  Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.

[42]  V. Jordan,et al.  Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[44]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[45]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[46]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[47]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[48]  M. Barbacid,et al.  vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. , 1989, The EMBO journal.

[49]  Dana M. Brantley-Sieders,et al.  Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA 2 Receptor Tyrosine Kinase * , 2008 .

[50]  G. Boivin,et al.  Targeted Overexpression of Vav 3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer , 2008 .

[51]  H. Hondermarck,et al.  The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. , 2005, Oncogene.

[52]  Yiwei Li,et al.  Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. , 2003, Oncogene.

[53]  S. Yeh,et al.  From HER 2 y Neu signal cascade to androgen receptor and its coactivators : A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells , 1999 .

[54]  P. Lara,et al.  Treatment options in androgen-independent prostate cancer. , 1999, Cancer investigation.

[55]  K. Ito,et al.  Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. , 1991, Receptor.